New combo tackles tough lymphoma in early trial

NCT ID NCT05270057

Ongoing Disease control Sponsor: Medical College of Wisconsin Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a new drug, loncastuximab tesirine, combined with a standard chemotherapy regimen (DA-EPOCH-R) in 11 adults with aggressive B-cell lymphomas. The main goal is to find the safest dose and check for side effects. It is not yet known if this combination will work better than current treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: loncastuximab tesirine combined with chemotherapy (DA-EPOCH-R)
What this could lead to: If successful, this could lead to a more effective treatment option for aggressive B-cell lymphomas, potentially improving disease control.
What could go wrong: This is a very early (Phase 1) and small trial (11 people) focused on safety, not effectiveness. The combination may cause severe side effects or not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell neoplasm Burkitt lymphoma EZB-MYC+ diffuse large B-cell lymphoma high grade B-cell lymphoma high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement plasmablastic lymphoma primary mediastinal large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B CELL LYMPHOMA BURKITT LYMPHOMA

Contacts and locations

Locations

Froedtert Hospital & the Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
University of Texas Southwestern

Dallas, Texas, 75390, United States
University of Wisconsin School of Medicine and Public Health

Madison, Wisconsin, 53705, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.